METTL3 and metabolic dysfunction-associated steatotic liver disease: METTL3/14 in a non-alcoholic fatty liver disease (NAFLD) model increased the m6A modification and protein level of ATP citrate lyase (ACLY) and stearoyl-CoA desaturase 1 (SCD1), which promoted cholesterol production and lipid droplet deposition [89].